Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Prospective Cohort Study
100%
Clinical Biomarkers
100%
COVID-19
100%
Nucleocapsid Antigen
100%
Clinical Outcomes
100%
Virological Markers
100%
C-reactive Protein
83%
Interleukin-6
66%
Hazard Ratio
50%
Biomarker Trajectories
50%
Anti-nucleocapsid Antibody
50%
Chronic Kidney Disease
33%
D-dimer
33%
90-day Mortality
33%
Sustained Recovery
33%
Inflammation
16%
Placebo
16%
Uganda
16%
Intervention Program
16%
High Risk
16%
Singapore
16%
Spain
16%
Serial Measurements
16%
Comorbidity
16%
Clinical Characteristics
16%
Inflammatory Markers
16%
SARS-CoV-2 Infection
16%
Vaccine Program
16%
Clinical Factors
16%
Viral Replication
16%
Unvaccinated
16%
Switzerland
16%
Denmark
16%
Therapeutic Vaccine
16%
Poland
16%
Baseline Characteristics
16%
Baseline Factors
16%
Viral Burden
16%
Neutralizing Monoclonal Antibody
16%
Greece
16%
Worse Prognosis
16%
U.S. National Institutes of Health
16%
Ordinal Outcome
16%
Bamlanivimab
16%
Tixagevimab
16%
Sotrovimab
16%
Pathogenic Role
16%
Platform Trials
16%
Therapeutic Interventions
16%
Immune Dysregulation
16%
Antigen-reactive
16%
Anti-inflammatory Treatment
16%
Medicine and Dentistry
Biological Marker
100%
COVID-19
100%
Prospective Cohort Study
100%
Virus Nucleocapsid
100%
Antigen
66%
C Reactive Protein
55%
Interleukin 6
44%
Hazard Ratio
33%
Chronic Kidney Disease
22%
D-Dimer
22%
Infection
11%
All Cause Mortality
11%
Antivirus Agent
11%
Anti-Inflammatory Drug
11%
Severe Acute Respiratory Syndrome Coronavirus 2
11%
Virus Replication
11%
Inflammation
11%
Placebo
11%
Monoclonal Antibody
11%
Immune Dysregulation
11%
Comorbidity
11%
Pathogenesis
11%
Immunology and Microbiology
COVID-19
100%
Virus Nucleocapsid
100%
Antigen
66%
Blood Plasma
66%
C-Reactive Protein
55%
Interleukin 6
44%
Infectious Disease
11%
Inflammation
11%
Viral Replication
11%
Immune Dysregulation
11%
Viral Load
11%
Severe Acute Respiratory Syndrome Coronavirus 2
11%
Monoclonal Antibody
11%
All Cause Mortality
11%
Comorbidity
11%
Infection
11%